



JC10 Rec'd PCT/PTO 07 JUL 2005

PATENT APPLICATION

PCT #4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87373

Shuh NARUMIYA

Appln. No.: 10/530,752

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: April 8, 2005

For: THERAPEUTIC AGENT FOR ALLERGIC DISEASES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant submits the following explanations: GB 1 521 688 corresponds to JP 51-125255 and GB 2 174 702 corresponds to JP 61-249951. Additionally, Applicants submit English language Abstracts for JP 11-012249, JP 10-168056, JP 7-233145, EP 0 139 608 and WO 97/05091.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Abraham J. Rosner
Registration No. 33,276

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 7, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/530,752
Confirmation Number	Not Yet Assigned
Filing Date	April 8, 2005
First Named Inventor	Shuh NARUMIYA
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q87373

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,624,959		04-29-1997	NAGAO et al.
		US 5,723,493		03-03-1998	NAGAO et al.
		US 5,753,700		05-19-1998	NAGAO et al.
		US 6,013,673		01-11-2000	NAGAO et al.
		US 4,692,464		09-08-1987	SKUBALLA et al.
		US 4,863,961		09-05-1989	COLLINS et al.
		US 3,985,791		10-12-1976	MUCHOWSKI et al.
		US 3,965,143		06-22-1976	COLLINS et al.
		US 4,301,146		11-17-1981	SANVORDEKER
		US 2,868,691		01-13-1959	PORUSH et al.
		US 3,095,355		06-25-1963	ABRAMSON et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		JP	11-12249		01-19-1999	TAISHO PHARMACEUT CO LTD	Abstract
		JP	10-168056		06-23-1998	TAISHO PHARMACEUT CO LTD	Abstract
		JP	7-233145		09-05-1995	TAISHO PHARMACEUT CO LTD	Abstract
		JP	51-125255		11-01-1976	MAY & BAKER LTD	
		JP	61-249951		11-07-1986	GLAXO GROUP LTD	
		WO	99/25358		05-27-1999	ALLERGAN SALES, INC.	Abstract
		GB	1 419 221		12-24-1975	ONO PHARMACEUTICAL CO., LTD.	
		GB	1 351 238		04-24-1974	ONO PHARMACEUTICAL CO., LTD.	
		GB	2 174 702	A	11-12-1986	GLAXO GROUP LIMITED	
		GB	1 521 688		08-16-1978	MAY & BAKER LIMITED	
		EP	0 139 608	A2	10-10-1984	SCHERING AKTIENGESELLSCHAFT	Abstract
		WO	97/05091		02-13-1997	ONO PHARMACEUTICAL CO., LTD.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		C.L. CHAN, et al.; "Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells"; British Journal of Pharmacology (2000) Vol. 129; pp. 589-597	
		James G. MARTIN, et al.; "The Immunomodulatory Actions of Prostaglandin E ₂ on Allergic Airway Responses in the Rat"; The Journal of Immunology; 2002; pp. 3963-3969	
		Stephen J. TILLEY, et al.; "Receptors and pathways mediating the effects of prostaglandin E ₂ on airway tone"; AJP-Lung Cell Mol Physiol; Vol. 284; April 2003; pp. L598-L606	
		Peter R. A. JOHNSON, et al.; "Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism"; J Allergy Clin Immunol; Vol. 13, No. 4, pp. 690-696	
		Tomonori KUNIKATA, et al.; "Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3"; Nature Immunology; Vol. 6, No. 5, May 2005; pp. 524-531	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.